News | March 19, 2024
Dr. Reddy's Laboratories launches Versavo in the UK
Versavo is the first Dr. Reddy's biosimilar product to be approved and launched in the UK
Versavo is the first Dr. Reddy's biosimilar product to be approved and launched in the UK
The acquisition is done through cash consideration, by way of conversion of SAFE (Simple Agreement for Future Equity) investment of US$ 2 Million to Preferred A-1 Shares
Dr. Reddy's Laboratories has been issued a Form 483 with three observations
The inspection closed with zero observations and a classification of No Action Indicated
The company has reported total income of Rs. 6738.4 crores during the period ended June 30, 2023
Shivalik Rasayan Limited has issued LOA to Medicamen Biotech to use its DMF grade Bortezomib API for formulation of Bortezomib injection 3.5mg/ vial
Dr. Reddy's Laboratories has been issued a Form 483 with four observations
The portfolio includes approximately 45 commercial products, four pipeline products and 40 approved non-marketed products, including a number of generic products focused on women’s health.
The Durezol brand and generic had US sales of approximately US $40 million MAT for the most recent twelve months ending in Nov 2022 according to IQVIA
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)